ERBB2 and breast carcinoma: We have also investigated whether the newly identified miRNA-based strategy, targeting of erbB3 with two functional cooperative miRNAs, can significantly enhance the anti-proliferative/anti-survival effects of trastuzumab and paclitaxel on HER2-overexpressing breast cancer cells.